Aishwarya Dande

About

Ph.D. scientist with expertise in LC-HRMS based analytical workflows, integrating metabolomics, proteomics, and bioanalytical method development for pharmaceutical applications and understanding of biological systems. My doctoral research focused on nitrosamine formation and attenuation, investigated through LC-HRMS-based targeted small-molecule analysis integrated with in vitro, in vivo, and stability studies. Beyond doctoral dissertation, I have significantly contributed to multiple proteomic and metabolomic projects, involving optimization of sample preparation protocols, method development, and data interpretation using various bioinformatic tools leading to several peer-reviewed publications.

Employment

• Virchow Biotech Pvt. Ltd. Internship
  2020 - 2021

Education

• National Institute of Pharmaceutical Education and Research PhD
  2021 - 2026
• G Pulla Reddy College of Pharmacy, Osmania University Master of Pharmacy (M. Pharm)
  2019 - 2021
• Gokaraju Rangaraju College of Pharmacy, Osmania University Bachelor of Pharmacy (B. Pharm)
  2015 - 2019

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• Discovering metabolic pathways associated with immune activation in people living with HIV following ChAdOx1 nCoV-19 vaccination using mass spectrometry
  Journal of Pharmaceutical and Biomedical Analysis 2026 DOI: 10.1016/j.jpba.2025.117215
  +Save
• Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery
  European Journal of Pharmaceutics and Biopharmaceutics 2025 DOI: 10.1016/j.ejpb.2025.114780
  +Save
• LC-ESI-HRMS-Based Evaluation of Antioxidants as Additives to Inhibit Genotoxic Nitrosamine Formation in Metformin Hydrochloride Tablets
  AAPS PharmSciTech 2025 DOI: 10.1208/s12249-025-03202-8
  +Save
• Highly selective ergosterol binding and impaired redox balance leads to improved antileishmanial efficacy for amphotericin b synthesized silver nanoparticles with reduced toxicity– In vitro and in vivo studies
  Free Radical Biology and Medicine 2025 DOI: 10.1016/j.freeradbiomed.2025.03.033
  +Save
• Risk Assessment, Detection and Control of Mutagenic Impurities in Pharmaceuticals: Emphasis on Nitrosamines
  Critical Reviews in Analytical Chemistry 2025 DOI: 10.1080/10408347.2025.2517357
  +Save
• Mechanistic and metabolic exploration of neohesperidin against lung cancer cell lines through ROS-mediated mitochondrial apoptosis: An in-silico and in-vitro approach
  Toxicology and Applied Pharmacology 2025 DOI: 10.1016/j.taap.2025.117350
  +Save
• Nitrosamine Drug Substance-Related Impurities (NDSRIs) in Pharmaceuticals: Formation, Mitigation Strategies, and Emphasis on Mutagenicity Risks
  Pharmaceutical Research 2025 DOI: 10.1007/s11095-025-03857-9
  +Save
• Analytical quality by design (AQbD) in the ICHQ14 guidelines for analytical procedure development
  Accreditation and Quality Assurance 2025 DOI: 10.1007/s00769-024-01587-w
  +Save
• Temperature- and time-dependent degradation of mouse tissue proteins: insights into RNA-binding protein stability via mass spectrometry
  Molecular Omics 2025 DOI: 10.1039/d5mo00020c
  +Save
• Identification and in vitro genotoxicity assessment of forced degradation products of glimepiride and glyburide using HEK cell‐based COMET assay
  Biomedical Chromatography 2024 DOI: 10.1002/bmc.6025
  +Save